Permissive regulation: A critical review of the regulatory history of buprenorphine formulations in Canada

Abhimanyu Sud; Meghan McGee; Barbara Mintzes; Matthew Herder

doi:10.1016/j.drugpo.2022.103749

Permissive regulation: A critical review of the regulatory history of buprenorphine formulations in Canada

Abhimanyu Sud, Meghan McGee, Barbara Mintzes, Matthew Herder

Psychology

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Original language	English
Article number	103749
Journal	International Journal of Drug Policy
Volume	105
DOIs	https://doi.org/10.1016/j.drugpo.2022.103749
Publication status	Published - Jul 2022

ASJC Scopus Subject Areas

Health Policy
Medicine (miscellaneous)

Keywords

Buprenorphine
Buprenorphine naloxone drug combination
Drug legislation
Generic drugs
Health policy
Opioid-related disorders

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.drugpo.2022.103749

Cite this

Sud, A., McGee, M., Mintzes, B., & Herder, M. (2022). Permissive regulation: A critical review of the regulatory history of buprenorphine formulations in Canada. International Journal of Drug Policy, 105, Article 103749. https://doi.org/10.1016/j.drugpo.2022.103749

@article{416fd0ee90884881be1bf33e1151c89f,

title = "Permissive regulation: A critical review of the regulatory history of buprenorphine formulations in Canada",

keywords = "Buprenorphine, Buprenorphine naloxone drug combination, Drug legislation, Generic drugs, Health policy, Opioid-related disorders",

author = "Abhimanyu Sud and Meghan McGee and Barbara Mintzes and Matthew Herder",

note = "Publisher Copyright: {\textcopyright} 2022 The Authors",

year = "2022",

month = jul,

doi = "10.1016/j.drugpo.2022.103749",

language = "English",

volume = "105",

journal = "International Journal of Drug Policy",

issn = "0955-3959",

publisher = "Elsevier",

}

TY - JOUR

T1 - Permissive regulation

T2 - A critical review of the regulatory history of buprenorphine formulations in Canada

AU - Sud, Abhimanyu

AU - McGee, Meghan

AU - Mintzes, Barbara

AU - Herder, Matthew

PY - 2022/7

Y1 - 2022/7

KW - Buprenorphine

KW - Buprenorphine naloxone drug combination

KW - Drug legislation

KW - Generic drugs

KW - Health policy

KW - Opioid-related disorders

UR - http://www.scopus.com/inward/record.url?scp=85133103079&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85133103079&partnerID=8YFLogxK

U2 - 10.1016/j.drugpo.2022.103749

DO - 10.1016/j.drugpo.2022.103749

M3 - Article

C2 - 35643048

AN - SCOPUS:85133103079

SN - 0955-3959

VL - 105

JO - International Journal of Drug Policy

JF - International Journal of Drug Policy

M1 - 103749

ER -

Permissive regulation: A critical review of the regulatory history of buprenorphine formulations in Canada

ASJC Scopus Subject Areas

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this